Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease
IntroductionPatients on dialysis and kidney transplant recipients (KTR) present the syndrome of mineral and bone disorders (MBD), which share common traits with monogenic calcifying diseases related to disturbances of the purinergic system. Low plasma levels of inorganic pyrophosphate (PPi) and ecto...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2020.586831/full |
id |
doaj-5e403959d0e6429d81e33fb53be5331f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Audrey Laurain Audrey Laurain Audrey Laurain Isabelle Rubera Christophe Duranton Frank Rutsch Yvonne Nitschke Elodie Ray Sandor Vido Antoine Sicard Antoine Sicard Georges Lefthériotis Georges Lefthériotis Georges Lefthériotis Guillaume Favre Guillaume Favre Guillaume Favre |
spellingShingle |
Audrey Laurain Audrey Laurain Audrey Laurain Isabelle Rubera Christophe Duranton Frank Rutsch Yvonne Nitschke Elodie Ray Sandor Vido Antoine Sicard Antoine Sicard Georges Lefthériotis Georges Lefthériotis Georges Lefthériotis Guillaume Favre Guillaume Favre Guillaume Favre Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease Frontiers in Cell and Developmental Biology alkaline phosphatase activity hemodialysis kidney transplant pyrophosphate purinergic mechanisms mineral and bone disorder (CKD-MBD) |
author_facet |
Audrey Laurain Audrey Laurain Audrey Laurain Isabelle Rubera Christophe Duranton Frank Rutsch Yvonne Nitschke Elodie Ray Sandor Vido Antoine Sicard Antoine Sicard Georges Lefthériotis Georges Lefthériotis Georges Lefthériotis Guillaume Favre Guillaume Favre Guillaume Favre |
author_sort |
Audrey Laurain |
title |
Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease |
title_short |
Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease |
title_full |
Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease |
title_fullStr |
Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease |
title_full_unstemmed |
Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease |
title_sort |
alkaline phosphatases account for low plasma levels of inorganic pyrophosphate in chronic kidney disease |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Cell and Developmental Biology |
issn |
2296-634X |
publishDate |
2020-12-01 |
description |
IntroductionPatients on dialysis and kidney transplant recipients (KTR) present the syndrome of mineral and bone disorders (MBD), which share common traits with monogenic calcifying diseases related to disturbances of the purinergic system. Low plasma levels of inorganic pyrophosphate (PPi) and ectopic vascular calcifications belong to these two conditions. This suggests that the purinergic system may be altered in chronic kidney disease with MBD. Therefore, we perform a transversal pilot study in order to compare the determinants of PPi homeostasis and the plasma levels of PPi in patients on dialysis, in KTR and in healthy people.Patients and MethodsWe included 10 controls, 10 patients on maintenance dialysis, 10 early KTR 3 ± 1 months after transplantation and nine late KTR 24 ± 3 months after transplantation. We measured aortic calcifications, plasma and urine levels of PPi, the renal fractional excretion of PPi (FePPi), nucleoside triphosphate hydrolase (NPP) and ALP activities in plasma. Correlations and comparisons were assessed with non-parametric tests.ResultsLow PPi was found in patients on dialysis [1.11 (0.88–1.35), p = 0.004], in early KTR [0.91 (0.66–0.98), p = 0.0003] and in late KTR [1.16 (1.07–1.45), p = 0.02] compared to controls [1.66 (1.31–1.72) μmol/L]. Arterial calcifications were higher in patients on dialysis than in controls [9 (1–75) vs. 399 (25–526) calcium score/cm2, p < 0.05]. ALP activity was augmented in patients on dialysis [113 (74–160), p = 0.01] and in early KTR [120 (84–142), p = 0.002] compared to controls [64 (56–70) UI/L]. The activity of NPP and FePPi were not different between groups. ALP activity was negatively correlated with PPi (r = −0.49, p = 0.001).DiscussionPatients on dialysis and KTR have low plasma levels of PPi, which are partly related to high ALP activity, but neither to low NPP activity, nor to increased renal excretion of PPi. Further work is necessary to explore comprehensively the purinergic system in chronic kidney disease. |
topic |
alkaline phosphatase activity hemodialysis kidney transplant pyrophosphate purinergic mechanisms mineral and bone disorder (CKD-MBD) |
url |
https://www.frontiersin.org/articles/10.3389/fcell.2020.586831/full |
work_keys_str_mv |
AT audreylaurain alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT audreylaurain alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT audreylaurain alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT isabellerubera alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT christopheduranton alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT frankrutsch alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT yvonnenitschke alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT elodieray alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT sandorvido alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT antoinesicard alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT antoinesicard alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT georgesleftheriotis alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT georgesleftheriotis alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT georgesleftheriotis alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT guillaumefavre alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT guillaumefavre alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease AT guillaumefavre alkalinephosphatasesaccountforlowplasmalevelsofinorganicpyrophosphateinchronickidneydisease |
_version_ |
1724390841296879616 |
spelling |
doaj-5e403959d0e6429d81e33fb53be5331f2020-12-08T08:35:23ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2020-12-01810.3389/fcell.2020.586831586831Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney DiseaseAudrey Laurain0Audrey Laurain1Audrey Laurain2Isabelle Rubera3Christophe Duranton4Frank Rutsch5Yvonne Nitschke6Elodie Ray7Sandor Vido8Antoine Sicard9Antoine Sicard10Georges Lefthériotis11Georges Lefthériotis12Georges Lefthériotis13Guillaume Favre14Guillaume Favre15Guillaume Favre16Faculty of Medicine, Côte d’Azur University, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceNephrology Department, University Hospital, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceDepartment of General Pediatrics, Muenster University Children’s Hospital, Muenster, GermanyDepartment of General Pediatrics, Muenster University Children’s Hospital, Muenster, GermanyDepartment of Vascular Medicine and Surgery, University Hospital, Nice, FranceNephrology Department, University Hospital, Nice, FranceFaculty of Medicine, Côte d’Azur University, Nice, FranceNephrology Department, University Hospital, Nice, FranceFaculty of Medicine, Côte d’Azur University, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceDepartment of Vascular Medicine and Surgery, University Hospital, Nice, FranceFaculty of Medicine, Côte d’Azur University, Nice, FranceUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, FranceNephrology Department, University Hospital, Nice, FranceIntroductionPatients on dialysis and kidney transplant recipients (KTR) present the syndrome of mineral and bone disorders (MBD), which share common traits with monogenic calcifying diseases related to disturbances of the purinergic system. Low plasma levels of inorganic pyrophosphate (PPi) and ectopic vascular calcifications belong to these two conditions. This suggests that the purinergic system may be altered in chronic kidney disease with MBD. Therefore, we perform a transversal pilot study in order to compare the determinants of PPi homeostasis and the plasma levels of PPi in patients on dialysis, in KTR and in healthy people.Patients and MethodsWe included 10 controls, 10 patients on maintenance dialysis, 10 early KTR 3 ± 1 months after transplantation and nine late KTR 24 ± 3 months after transplantation. We measured aortic calcifications, plasma and urine levels of PPi, the renal fractional excretion of PPi (FePPi), nucleoside triphosphate hydrolase (NPP) and ALP activities in plasma. Correlations and comparisons were assessed with non-parametric tests.ResultsLow PPi was found in patients on dialysis [1.11 (0.88–1.35), p = 0.004], in early KTR [0.91 (0.66–0.98), p = 0.0003] and in late KTR [1.16 (1.07–1.45), p = 0.02] compared to controls [1.66 (1.31–1.72) μmol/L]. Arterial calcifications were higher in patients on dialysis than in controls [9 (1–75) vs. 399 (25–526) calcium score/cm2, p < 0.05]. ALP activity was augmented in patients on dialysis [113 (74–160), p = 0.01] and in early KTR [120 (84–142), p = 0.002] compared to controls [64 (56–70) UI/L]. The activity of NPP and FePPi were not different between groups. ALP activity was negatively correlated with PPi (r = −0.49, p = 0.001).DiscussionPatients on dialysis and KTR have low plasma levels of PPi, which are partly related to high ALP activity, but neither to low NPP activity, nor to increased renal excretion of PPi. Further work is necessary to explore comprehensively the purinergic system in chronic kidney disease.https://www.frontiersin.org/articles/10.3389/fcell.2020.586831/fullalkaline phosphatase activityhemodialysiskidney transplantpyrophosphatepurinergic mechanismsmineral and bone disorder (CKD-MBD) |